Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor (G‑CSF) analog presented as a sterile solution for intravenous and subcutaneous use. It stimulates proliferation and differentiation of neutrophil precursors, increasing neutrophil counts in patients with compromised bone‑marrow function such as those undergoing chemotherapy, bone‑marrow transplantation, or affected by aplastic or congenital neutropenia.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Neupogen (filgrastim) is a hematopoietic growth factor used to manage conditions associated with low neutrophil counts.

- Chemotherapy‑induced neutropenia: shortens the duration of neutropenia and reduces infection risk. - Aplastic anemia: promotes neutrophil recovery in patients with bone‑marrow failure. - Bone marrow transplantation: supports neutrophil engraftment after transplant procedures. - Congenital neutropenia: increases neutrophil production in inherited neutropenia disorders.

Filgrastim may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bone pain: aching discomfort, often in the limbs or back. - Injection site reactions: redness, swelling or tenderness. - Fever: mild to moderate temperature elevation. - Headache: transient cranial discomfort. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness or weakness.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and signs of internal bleeding. - Acute respiratory distress syndrome: severe breathing difficulty. - Anaphylaxis or severe allergic reaction: hives, swelling, airway compromise. - Leukocytosis: excessively high white‑blood‑cell count. - Capillary leak syndrome: fluid accumulation and low blood pressure. - Severe bone pain requiring opioid analgesia.

When prescribing filgrastim, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: monitor renal function and adjust monitoring frequency. - Sickle cell disease: increased risk of vaso‑occlusive crises; observe closely. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Concurrent chemotherapy: closely monitor blood counts for additive myelosuppression. - History of splenomegaly: assess for splenic enlargement and watch for rupture signs. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other colony‑stimulating factors: may cause excessive leukocytosis. - Live vaccines: heightened risk of infection due to altered immune response. - High‑dose corticosteroids: can diminish filgrastim’s neutrophil‑stimulating effect.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., quinolones): may interfere with neutrophil function. - Immunosuppressants (e.g., cyclosporine): may alter response to filgrastim. - Allopurinol: increased chance of hypersensitivity reactions.